PRP Effectiveness in Knee Osteoarthritis
PRP
Comparative Efficacy of Two Platelet-Rich Plasma Treatments For Knee Osteoarthritis: A Double-Blind Randomized Controlled Trial
1 other identifier
interventional
96
1 country
1
Brief Summary
The aim of our study is to determine the effects of intra-articular Platelet-Rich Plasma (PRP) prepared with two different techniques on pain intensity, functional status, quality of life, functional balance and femoral cartilage thickness in patients with knee osteoarthritis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable knee-osteoarthritis
Started May 2021
Typical duration for not_applicable knee-osteoarthritis
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 17, 2021
CompletedFirst Posted
Study publicly available on registry
March 19, 2021
CompletedStudy Start
First participant enrolled
May 20, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2023
CompletedMay 22, 2026
March 1, 2023
1.5 years
March 17, 2021
May 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline activity pain score at 1-months, 3-months and 6-months
Visual Analogue Scale-Activity pain (0-10 point). Higher scores mean a worse outcome
Baseline, 1-month, 3-month, 6-month
Secondary Outcomes (5)
Change from baseline activity pain score at 1-months, 3-months and 6-months
Baseline, 1-month, 3-month, 6-month
Change from baseline pain, stiffness and physical function at 1-months, 3-months and 6-months
Baseline, 1-month, 3-month, 6-month
Change from baseline quality of life and global assessment at 1-months, 3-months and 6-months
Baseline, 1-month, 3-month, 6-month
Change from baseline functional balance at 3-months and 6-months
Baseline, 3-month, 6-month
Change from baseline femoral cartilage thickness measurement by ultrasound at 6 months
Baseline, 6-month
Study Arms (3)
T-LAB / NEXT PRP SYRINGE
ACTIVE COMPARATORIn the first group (PRP1 group; non-anticoagulant pure PRP), prepared with Next PRP Syringe in 3 sessions will be applied.
T-LAB / PRP KIT
ACTIVE COMPARATORIn the second group (PRP2 group; amber PRP) prepared with T-LAB / PRP KIT in 3 sessions will be applied.
SALINE
SHAM COMPARATORIn the third group (saline group), prepared with SALINE in 3 sessions will be applied.
Interventions
PRP containing anticoagulant will be prepared using T-LAB / PRP KIT. 4 ml of PRP will be injected intra-articularly three times at 2-week intervals. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, and short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Similar to the PRP protocol, 4 mL of 0.9% sodium chloride will be injected intra-articularly. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, and short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Anticoagulant-free pure PRP will be prepared using T-LAB / Next PRP Syringe. 4 ml of PRP will be injected intra-articularly three times at 2-week intervals. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, and short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Eligibility Criteria
You may qualify if:
- Patients with chronic symptomatic knee pain between the ages of 30 and 75 years
- Presence of Kellgren-Lawrence stage 2-3 osteoarthritis on current anterior-posterior knee radiographs
- The ability to walk independently
You may not qualify if:
- Previous treatment with an autologous blood product or stem cell preparation
- Severe knee effusion
- Concomitant severe meniscus or ligament injury
- Recent cancer or other tumors
- History of knee surgery
- Previous diagnosis of a neuromuscular, infectious, or inflammatory disease
- Bleeding disorders and/or use of warfarin
- Body mass index above 40 kg/m²
- Cardiac or systemic diseases that could affect participation in the exercise program
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation
Istanbul, Fatıh, 34034, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Demirhan Diracoglu, Prof.
Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation
- PRINCIPAL INVESTIGATOR
Ekin I Sen, Asst. Prof.
Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, Sub-Investigator
Study Record Dates
First Submitted
March 17, 2021
First Posted
March 19, 2021
Study Start
May 20, 2021
Primary Completion
November 20, 2022
Study Completion
January 1, 2023
Last Updated
May 22, 2026
Record last verified: 2023-03